Alnylam Pharmaceuticals (ALNY) is a Great Momentum Stock: Should You Buy?

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, with the aim of buying high and selling higher, leveraging established price movements for profitable trades [1]. Company Overview: Alnylam Pharmaceuticals (ALNY) - Alnylam Pharmaceuticals currently holds a Momentum Style Score of A, indicating strong momentum characteristics [1]. - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook based on historical performance metrics [2]. Performance Metrics - Over the past week, ALNY shares increased by 4.08%, outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 2.24% [3]. - In the last month, ALNY's price change was 9.4%, significantly higher than the industry's 1.44% [3]. - Over the past quarter, ALNY shares have risen by 26.8%, and they have increased by 80.82% over the last year, compared to the S&P 500's gains of 5.5% and 40.28%, respectively [3]. Trading Volume - ALNY's average 20-day trading volume is 740,644 shares, which serves as a bullish indicator when combined with rising stock prices [3]. Earnings Outlook - In the last two months, one earnings estimate for ALNY has increased while one has decreased, leading to a consensus estimate improvement from -$0.83 to -$0.64 [4]. - For the next fiscal year, one estimate has moved upwards, while three have been revised downwards [4]. Conclusion - Given the strong performance metrics and positive earnings outlook, ALNY is positioned as a solid momentum pick with a Momentum Score of A and a Zacks Rank of 2 (Buy) [4].